All these might be attributed to the fact that apatinib, as an oral small molecule TKI against angiogenesis, can block VEGFR-2 in advanced GCA patients and reduce the activation of mitogen-activated protein kinase, thus inhibiting the proliferation of vascular endothelial cells. This evidence concerns the gene WNK2 and temporal arteritis.